Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 adjuvant nivolumab versus placebo in high-risk invasive urothelial carcinoma
CTR20170693Phase 3Active
- Sponsor
- Bristol Myers Squibb
- Start
- Oct 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of nivolumab in transitional cell carcinoma (TCC), sponsored by Bristol Myers Squibb. Started Oct 2017; status: active.
02
Drugs
03
Conditions
transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on CTR20170693.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20170693.